Rupert Sandbrink
Rupert Sandbrink
Topas Therapeutics GmbH
Adresse e-mail validée de topas-therapeutics.com
Titre
Citée par
Citée par
Année
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
JS Heier, DM Brown, V Chong, JF Korobelnik, PK Kaiser, QD Nguyen, ...
Ophthalmology 119 (12), 2537-2548, 2012
19912012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...
The lancet 380 (9856), 1829-1839, 2012
10062012
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ...
Neurology 67 (7), 1242-1249, 2006
9372006
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies
U Schmidt-Erfurth, PK Kaiser, JF Korobelnik, DM Brown, V Chong, ...
Ophthalmology 121 (1), 193-201, 2014
7252014
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the …
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet 370 (9585), 389-397, 2007
6782007
Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
N Ida, T Hartmann, J Pantel, J Schröder, R Zerfass, H Förstl, R Sandbrink, ...
Journal of Biological Chemistry 271 (37), 22908-22914, 1996
5921996
Vitamin D as an early predictor of multiple sclerosis activity and progression
A Ascherio, KL Munger, R White, K Köchert, KC Simon, CH Polman, ...
JAMA neurology 71 (3), 306-314, 2014
4872014
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ...
The Lancet Neurology 8 (10), 889-897, 2009
4862009
One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema
DV Do, QD Nguyen, D Boyer, U Schmidt-Erfurth, DM Brown, R Vitti, ...
Ophthalmology 119 (8), 1658-1665, 2012
4392012
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 …
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet Neurology 8 (11), 987-997, 2009
4042009
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study
DM Brown, JS Heier, WL Clark, DS Boyer, R Vitti, AJ Berliner, O Zeitz, ...
American journal of ophthalmology 155 (3), 429-437. e7, 2013
3652013
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema
DV Do, U Schmidt-Erfurth, VH Gonzalez, CM Gordon, M Tolentino, ...
Ophthalmology 118 (9), 1819-1826, 2011
3212011
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci
NA Patsopoulos, PIW de Bakker
Annals of neurology 70 (6), 897-912, 2011
3152011
Lack of association between antimyelin antibodies and progression to multiple sclerosis
J Kuhle, C Pohl, M Mehling, G Edan, MS Freedman, HP Hartung, ...
New England Journal of Medicine 356 (4), 371-378, 2007
2822007
Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study
JF Korobelnik, FG Holz, J Roider, Y Ogura, C Simader, U Schmidt-Erfurth, ...
Ophthalmology 121 (1), 202-208, 2014
2682014
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study
D Boyer, J Heier, DM Brown, WL Clark, R Vitti, AJ Berliner, G Groetzbach, ...
Ophthalmology 119 (5), 1024-1032, 2012
2672012
Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study
JS Heier, WL Clark, DS Boyer, DM Brown, R Vitti, AJ Berliner, H Kazmi, ...
Ophthalmology 121 (7), 1414-1420. e1, 2014
2602014
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score
PL De Jager, LB Chibnik, J Cui, J Reischl, S Lehr, KC Simon, C Aubin, ...
The Lancet Neurology 8 (12), 1111-1119, 2009
2472009
VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study
FG Holz, J Roider, Y Ogura, JF Korobelnik, C Simader, G Groetzbach, ...
British Journal of Ophthalmology, bjophthalmol-2012-301504, 2013
2322013
Beta A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons.
R Sandbrink, CL Masters, K Beyreuther
Journal of Biological Chemistry 269 (2), 1510-1517, 1994
2071994
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20